NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells
Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Cristina Lombari(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Gabriele Conforti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimiliano Berretta(University of Messina), Stefania Cocco(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonietta Caronna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppina Rea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annamaria Bonelli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 82
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460